Figure 5. NA exhibits vasorelaxing and anti-hypertensive effects by activating the CCK system in SHR in the advanced stage. Effects of different inhibitors of vasorelaxing activity of NA (A). The dose dependency of the vasorelaxing activity of NA (B). NA-induced anti-hypertensive effects were blocked by lorglumide, an antagonist for the CCK receptor (C). Values are expressed as the means ± SEM (A, n = 3-4; B, n = 5-8; C, n=4-7). *P < 0.05, compared with the NA group (A). *P < 0.05, compared with the control group. #P< 0.05 compared with the NA + lorglumide group (C).